Status:
COMPLETED
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level
Lead Sponsor:
Assiut University
Conditions:
Idiopathic Thrombocytopenic Purpura
Eligibility:
All Genders
Brief Summary
1. The purpose of this study is to investigate the expression of CD11a on subpopulation of lymphocytes and compared its expression between ITP patients and healthy controls and explores its possible r...
Detailed Description
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts with or without mucocutaneous bleeding (McMillan 2007). Like the majority of autoimmune diseases, ITP is an...
Eligibility Criteria
Inclusion
- newly diagnosed primary immune thrombocytopenic patients
Exclusion
- We will exclude patients with any other possible cause of thrombocytopenia either immune or non immune as:
- Patients with diabetes
- HCV
- other autoimmune disease (as SLE or RA)
- Chronic Liver or kidney disease
Key Trial Info
Start Date :
March 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03864796
Start Date
March 1 2019
End Date
January 1 2021
Last Update
January 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mona
Asyut, Egypt